Background: Adenoid cystic carcinoma (ACC) is an aggressive cancer with no curative treatment for patients with recurrent/ metastatic disease. The MYB-NFIB gene fusion is the main genomic hallmark and a potential therapeutic target. Methods: Oncogenic signaling pathways were studied in cultured cells and/or tumors from 15 ACC patients. Phosphoreceptor tyrosine kinase (RTK) arrays were used to study the activity of RTKs. Effects of RTK inhibition on cell proliferation were analyzed with AlamarBlue, sphere assays, and two ACC xenograft models (n ¼ 4-9 mice per group). The molecular effects of MYB-NFIB knockdown and IGF1R inhibition were studied with quantitative polymerase chain reaction, immunoblot, and gene expression microarrays. All statistical tests were two-sided. Results: The MYB-NFIB fusion drives proliferation of ACC cells and is crucial for spherogenesis. Intriguingly, the fusion is regulated through AKT-dependent signaling induced by IGF1R overexpression and is downregulated upon IGF1R-inhibition (% expression of control 6 SD ¼ 27.2 6 1.3, P < .001). MYB-NFIB regulates genes involved in cell cycle control, DNA replication/ repair, and RNA processing. The transcriptional program induced by MYB-NFIB affects critical oncogenic mediators normally controlled by MYC and is reversed by pharmacological inhibition of IGF1R. Co-activation of epidermal growth factor receptor (EGFR) and MET promoted proliferation of ACC cells, and combined targeting of IGFR1/EGFR/MET induced differentiation and synergistically inhibited the growth of patient-derived xenografted ACCs (ACCX5M1, % growth of control 6 SD ¼ 34.9 6 20.3, P ¼ .006; ACCX6, % growth of control 6 SD ¼ 24.1 6 17.5, P ¼ .04). Conclusions: MYB-NFIB is an oncogenic driver and a key therapeutic target in ACC that is regulated by AKT-dependent IGF1R signaling. Our studies uncover a new strategy to target an oncogenic transcriptional master regulator and provide new important insights into the biology and treatment of ACC.
The MYB-NFIB oncoproteins consist of the DNA-binding and transactivation domains of MYB linked to the C-terminal part of NFIB. The fusions disrupt the 3 0 -end of MYB, leading to loss of negative regulatory elements and to MYB overexpression (5) . Activation of MYB (or more rarely MYBL1) through gene fusion or juxtaposition of enhancer elements to these loci is the main genomic hallmark of ACC (5, (8) (9) (10) (11) (12) (13) . ACC has a unique gene expression signature (14) and a quiet genome with a low exonic somatic mutation rate, consistent with the view that MYB is the major oncogenic driver (5, 8, (15) (16) (17) (18) . ACC is one of the most common salivary gland cancers, but may also arise in other exocrine glands (8, 10) . It is an aggressive cancer with frequent local recurrences, perineural invasion, and distant metastases. ACC has a poor long-term prognosis, and there is no effective systemic treatment available for patients with advanced disease (19, 20) . Preclinical studies of ACC have been seriously hampered by the lack of bona fide ACC cell lines and transgenic mouse models (21, 22) .
The purpose of this study was to explore novel treatment options for ACC by targeting activated signaling pathways that regulate critical oncogenic drivers, including MYB. In addition, we studied the oncogenic properties of MYB and its role in ACC cell differentiation and spherogenesis.
Methods

Tumor Material and Cell Culture
Fresh tumor tissues were obtained from 15 MYB-NFIB translocation-positive ACCs (Table 1) (5, 16) . Cultured ACC cells were available from cases 1-3 (Table 1 ; Supplementary Figure  1A , available online) (5, 23, 24) . The study was approved by the regional ethics committee in Gothenburg, Sweden (D-No: 178-08). Additional details are available in the Supplementary Materials (available online).
Protein Expression, Phosphorylation Assays, and Gene Expression Analyses
Protein expression/phosphorylation were analyzed with Phospho-RTK Arrays (R&D Systems, Minneapolis, MN), immunoblot, and immunohistochemistry. Quantitative realtime polymerase chain reaction (qPCR) was performed using TaqMan assays (Thermo Fisher Scientific, Waltham, MA). Relative gene expression was calculated with the delta-delta cycle threshold (ddCT) method (25) . Global gene expression was studied using HuGene 1.0 ST microarrays (Affymetrix, Santa Clara, CA) and analyzed with Nexus Expression 3.0 (BioDiscovery, El Segundo, CA), gene set enrichment analysis (GSEA; GenePattern) (26) , and ingenuity pathway analysis (Qiagen, Hilden, Germany). Microarray data are available from the GEO database (Accession Nos. GSE76094 and GSE88804). Details are available in the Supplementary Materials (available online).
Cell Proliferation, Apoptosis, Cell Cycle, and Sphere Assays AlamarBlue (Thermo Fisher Scientific) and Caspase-Glo 3/7 (Promega, Madison, WI) were used to measure proliferation and apoptosis. Cell cycle analysis was performed with a FITC/BrdU flow kit (BD, Franklin Lakes, NJ). Sphere assays were done using PolyHEMA-coated plates. Detailed methods are described in the Supplementary Materials (available online).
TKI Treatments of ACC Xenografts
Two patient-derived ACC xenograft models (11, 27) were studied through the South Texas Accelerated Research Therapeutics program (START, San Antonio, TX). The gene expression profiles of xenografted tumors were validated against ACC patient samples using expression microarrays and unsupervised hierarchical clustering (Supplementary Figure 1B , available online). Female athymic nu/nu mice (4-6 weeks) were handled as described (28) and in accordance with the Institutional Animal Care and Use Committee guidelines. Mice (4-9 mice/group) were treated with linsitinib (25 mg/kg), crizotinib (50 mg/kg), and gefitinib (100 mg/kg). Detailed methods are available in the Supplementary Materials (available online). Szanto et al. (42) . †Primary tumor in the nasal mucosa.
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Dose-response curves were analyzed by nonlinear regression with Prism 6 (GraphPad Software, La Jolla, CA); IC 25 and IC 50 defined drug concentrations that reduced cell proliferation by 25% and 50%, respectively. For combination treatments, the definition of drug independence according to Bliss (29) was used; that is, two drugs were considered additive if the relative phenotypic effect E of each drug was independent of the presence of the other drug E AB ¼ E A E B , where E AB denotes the experimentally measured effect of combination and E A E B the expected effect of combination as calculated from single drug treatments. Synergy between two drugs was obtained when E AB > E A E B , and drug antagonism was obtained when E AB < E A E B . For estimation of triple drug additivity the formula was extended to E ABC ¼ E A E B E C , as described by Dressler et al. (30) . Differences between the experimentally measured effects of drug combinations and the expected effects calculated from single drug treatments were analyzed using a one-sample t test.
The statistical significance of overlap between microarray data sets was estimated using the chi-square test. Unsupervised hierarchical clustering was performed with Pearson correlation and pairwise average-linkage. qPCR data was analyzed with nonparametric Mann-Whitney test or independent sample t test, with post hoc F tests to confirm the assumption of equal variance within groups. All statistical tests were two-sided. A P value of less than .05 was considered statistically significant.
Results
Co-activated Receptor Tyrosine Kinases in ACC
Receptor tyrosine kinase (RTK) activation in ACC cells was explored using phospho-arrays. We observed strong activation of IGF1R, INSR, MET, and epidermal growth factor receptor (EGFR) in all three tested tumors ( Figure 1A) . Notably, the EGFR was phosphorylated in serum-starved cells, indicating constitutive EGFR activation. Next, we investigated the clinical Growth medium Serum-starved experiments. B) Treatment of two ACC patient-derived xenograft models with combinations of TKIs (mean 6 SEM, n ¼ 4-9 mice per group, independent sample t test).
C) Formalin-fixed, paraffin-embedded, hematoxylin and eosin-stained sections from ACCX6 untreated controls (upper panel) and TKI-treated tumors (lower panel).
Scale bar ¼ 50 lm. D) Quantitative real-time polymerase chain reaction (qPCR) analysis of MYB expression in untreated controls and TKI-treated xenografts from ACCX6 (n ¼ 7 control mice, n ¼ 5 treated mice, Mann-Whitney test, **P < .01). E) qPCR analysis of MYB expression in cultured ACC cells after 72-hour treatment with
TKIs at IC 50 concentrations (mean 6 SD, n ¼ 3, independent sample t test, ***P < .001). Data represent one of three independent experiments. F) In vitro growth morphology of control and TKI-treated ACC cells as in (E). Scale bar ¼ 25 lm. All statistical tests were two-sided.
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showing crosstalk between EGFR and MET ( Figure 1, C and D) . Moreover, ligand stimulation led to downstream activation of AKT and MAPK ( Figure 1E ). To investigate the biological relevance of IGF1R, INSR, MET, and EGFR signaling, we treated ACC cells with increasing concentrations of linsitinib (targets IGF1R/INSR), crizotinib (MET), and gefitinib (EGFR). Each drug decreased cell proliferation in a dose-dependent manner ( Figure 1F ). The average 25% and 50% inhibitory concentrations (IC 25 and IC 50 ) for gefitinib were 5.19 and 7.90 mM, respectively, which were higher than those of crizotinib (0.10 and 0.40 mM) and linsitinib (0.07 and 0.23 mM). Linsitinib and crizotinib each reduced ACC spherogenesis, whereas gefitinib did not ( Figure 1G ). At IC 25 and IC 50 , none of these TKIs induced apoptosis ( Figure 1H ). Thus, their antiproliferative effects reflect growth inhibition rather than increased cell death. These results demonstrate for the first time that analysis of MYB-NFIB expression in ACC cells treated with inhibitory concentrations (IC 50 ) of tyrosine kinase inhibitors (TKIs) for 72 hours (mean 6 SD, n ¼ 3, independent sample t test, ***P < .001). B) Immunoblot analysis of MYB-NFIB protein expression after TKI treatment as in (A). C) qPCR analysis of MYB-NFIB, IGF1R, and INSR expression in ACC cells after treatment with INSR or IGF1R small interferring RNA (siRNA) for 48 hours (mean 6 SD, n ¼ 3, independent sample t test, *P < .05, **P < .01, ***P < .001). D) Immunoblot analysis of MYB-NFIB protein expression after siRNA knockdown of INSR or IGF1R as in (C). E) Proliferation of ACC cells after IGF1R knockdown (mean 6 SD, n ¼ 6, independent sample t test, ***P < .001). F) qPCR analysis of MYB-NFIB expression in serum-starved ACC cells (24 hours) stimulated with 5 lg/mL insulin for 24 hours in the presence of MEK (trametinib) or AKT (MK-2206) inhibitors (mean 6 SD, n ¼ 3, independent sample t test, ***P < .001). G) qPCR analysis of MYB-NFIB expression in ACC cells treated with insulin, IGF1, or IGF2 (mean 6 SD, n ¼ 3, independent samples t test, **P < .01, ***P < .001). H) Immunoblot analysis of MYB-NFIB protein expression in ACC cells treated with insulin, IGF1, or IGF2 as in (G). I) qPCR analysis of IGF1 and IGF2 expression in ACC surgical specimens and three normal salivary glands (NSGs; horizontal lines indicate mean expression; Mann-Whitney test). J) qPCR analyses of IGF2 and MYB-NFIB expression after 72 hours of IGF2 knockdown (mean 6 SD, n ¼ 3, independent sample t test, **P < .01, ***P < .001). K) Immunoblot analysis of MYB-NFIB expression after 72 hours of IGF2 knockdown. Data shown represent one of three independent experiments. All statistical tests were two-sided. ACC ¼ adenoid cystic carcinoma; NSG ¼ normal salivary gland; RFU ¼ relative fluorescence units.
EGFR signaling pathways. In addition, triple TKI treatment caused a statistically significant downregulation of cell cycle regulators (P < .01) (Supplementary Figure 3B , available online). Next, we evaluated the effects of RTK inhibition on tumor growth in vivo using two patient-derived ACC xenograft models. Microarray analyses showed that both models had global gene expression signatures that were indistinguishable from primary ACC surgical samples (Supplementary Figure 1B , available online). Treatment with single TKIs did not inhibit tumor growth (data not shown). In contrast, combined treatment with linsitinib, crizotinib, and gefitinib significantly inhibited tumor growth in both ACC models (ACCX5M1, % growth of control 6 SD ¼ 34.9 6 20.3, P ¼ .006; ACCX6, % growth of control 6 SD ¼ 24.1 6 17.5, P ¼ .04) ( Figure 2B) . Histologically, the treated tumors showed enlarged nuclei, focal necrosis, and numerous psedocysts and duct-like structures filled with mucoid/eosinophilic materials, changes that were rarely or not seen in untreated tumors ( Figure 2C ). Importantly, MYB expression was also inhibited in TKI-treated tumors (% expression of control 6 SD ¼ 44.2 6 18.1, P ¼ .003) ( Figure 2D ). Similarly, TKI-treated cultured ACC cells showed decreased MYB expression (% expression of control 6 SD ¼ 19.3 6 6.1, P < .001) ( Figure 2E ), increased cell size, vacuolization, and a pronounced endoplasmatic reticulum ( Figure 2F ). Thus, combined targeting of IGF1R/INSR, MET, and EGFR downregulates MYB, inhibits tumor growth, and induces differentiation in ACC cells.
The Role of IGF1R/AKT Signaling in the Regulation of MYB-NFIB Expression
To investigate whether IGF1R/INSR, MET, or EGFR regulate expression of MYB-NFIB, we treated ACC cells with TKIs (IC 50 ) and measured expression of the fusion. Linsitinib decreased MYB-NFIB mRNA (% expression of control 6 SD ¼ 27.2 6 1.3, P < .001) and protein whereas crizotinib and gefitinib did not ( Figure 3 , A and B; Supplementary Figure 4A , available online). Importantly, linsitinib treatment reduced the expression of MYB-NFIB/MYB irrespective of the mechanism of MYB activation ( Figure 2D and Figure  3A ; Supplementary Figure 4A , available online). Cases 1 and 3 and ACCX5M1 express different MYB-NFIB fusion transcript variants whereas ACCX6 has MYB activation through juxtaposition of the TGFBR3 superenhancer to the MYB locus (5, 11, 27) . Notably, expression of the wild-type, nonfused MYB allele was undetectable or not reduced by linsitinib treatment (Supplementary Figure 4 , B-D, available online), whereas the expression of the wild-type, nonfused NFIB allele increased slightly after treatment (Supplementary Figure 4B , available online). Hence, our results indicate that IGF1R specifically regulates the fused/activated MYB allele.
To further dissect the regulation of MYB-NFIB in ACC cells, we knocked down IGF1R and INSR with siRNAs. INSR knockdown slightly increased MYB-NFIB mRNA but did not affect protein expression. In contrast, IGF1R knockdown decreased MYB-NFIB mRNA by 50% to 60%, eliminated protein expression, and reduced cell proliferation (Figure 3, C-E) .
To identify the pathway downstream of IGF1R that regulates MYB-NFIB, we stimulated serum-starved ACC cells with insulin in the presence of MEK or AKT inhibitors ( Figure 3F ). The AKT inhibitor MK-2206 blocked insulin-dependent MYB-NFIB expression, whereas the MEK inhibitor did not, demonstrating that MYB-NFIB is regulated by IGF1R in an AKT-dependent manner. (qPCR) analysis of MYB-NFIB expression after MYB small interfering RNA (siRNA) treatment for 48 hours (mean 6 SD, n ¼ 3, independent sample t test, **P < .01, ***P < .001). B) Immunoblot analysis of MYB-NFIB protein expression as in (A). C) Proliferation of ACC cells after MYB-NFIB knockdown (mean 6 SD, n ¼ 6, independent sample t test, ***P < .001). D) Relative apoptosis measured as caspase 3/7 activity in ACC cells transfected with MYB siRNAs for 96 hours (mean 6 SD, n ¼ 3). E) Sphere formation after MYB-NFIB knockdown in ACC cells (mean 6 SD, n ¼ 6, independent sample t test, ***P < .001). Data shown represent one of three independent experiments. All statistical tests were two-sided. RFU ¼ relative fluorescence units. H   NAV3  TMEM144  GINS1  SEMA3A  PTPRZ1  FGFBP1  FIGNL1  APOOL  KCNC1  SFN  AADACL1  SLC2A1  PLEK2  UTP20  ODC1  FAM83B  EPGN  FAM83A  GOLSYN  LYAR  TUFT1  C10orf78  FAM33A  CDCA7  CHAC2  CDC6  POFUT1  EPB41L2  SFXN2  CTPS  NP  CA2  TOMM22  GDAP1  SNORA61  SLC47A1  ZWILCH  C1orf116  LOC729012  MYB  FAM83D  CENPI  EXO1  FJX1  SNORA56  LRP8 IGF2  ITPR1  ABCA8  CCDC68  SLC38A4  C4orf34  PLSCR4  FAM65B  SPOPL  HIPK3  ARL6IP6  PGM2L1  PTGFR  EVI2B  CASP1  TMEM65  LATS2  RUNX2  RCAN2  TK2  TGFB2  KCNT2  ATP11A  SGCE  F2R  REPS2  MGAT4B  PLXDC2  ROR2  SLC7A2  ROR1  GALNTL2  CHST7  ZC3H6  SORBS2  CEP170L  FMO2  KIAA1305  SMOC1  CYBRD1  PRKCH  PDK4  C9orf3  ETV1  PELI2  SLC17A5  LONRF1  MMP7  TSC22D3  FAIM  - 
Effects of IGF2 on MYB-NFIB Expression
The Role of MYB-NFIB in ACC Cell Proliferation and Spherogenesis
To assess the biological significance of MYB-NFIB in ACC cells, we knocked down MYB-NFIB with MYB siRNAs. Knockdown resulted in G1 arrest, reduced cell proliferation, spherogenesis, and MYB-NFIB mRNA and protein expression, but did not increase apoptosis (Figure 4 , A-E; Supplementary Figure 5 , available online). These results demonstrate that the MYB-NFIB oncoprotein promotes cell proliferation and suggest that the fusion is required for tumor growth initiated by ACC stem/ stem-like cancer cells.
Impact of IGF1R Inhibition on the MYB-NFIB-Induced Transcriptional Program
To identify potential target genes and biological processes affected by MYB-NFIB, we analyzed the global gene expression pattern in ACC cells after siRNA knockdown of MYB-NFIB. Several hundred genes were downregulated (Supplementary Table 1 , available online), most with central cellular functions, such as DNA replication/repair, cell cycle regulation, and RNA processing ( Table 2) . Known MYB target genes (6) that were downregulated included, for example, CCNB1, FGF2, PPP3CA, and FABP5 ( Figure 5A ; Supplementary Figure 5B ). Ingenuity pathway analysis identified MYC as a top upstream transcriptional regulator after MYB-NFIB knockdown ( Figure 5C ). Thus, MYB-NFIB shares critical oncogenic features with MYC. Notably, MYC protein but not mRNA levels were reduced after MYB-NFIB knockdown ( Figure 5 , D and E), suggesting that MYB-NFIB indirectly regulates MYC target genes by altering MYC protein levels. Remarkably, gene expression analyses of ACC cells revealed a statistically significant overlap (P < .001) between genes affected by the IGF1R inhibitors linsitinib or BMS-754807 (both had similar effects; Figure 1 , C, D, F and G, and Figure 3A ; Supplementary Figure 6 , available online) and genes affected by MYB-NFIB knockdown ( Figure 5, F-I ). More than 50% of the genes downregulated by MYB-NFIB knockdown were also downregulated by IGF1R-inhibition (374 genes), demonstrating that the transcriptional program induced by MYB-NFIB is reversed by pharmacological inhibition of IGF1R. Notably, IGF2 was the most strongly upregulated gene after MYB-NFIB knockdown ( Figure 5 , I and J), suggesting a feedback loop between IGF2 and MYB-NFIB. Analysis of the 374 genes downregulated by MYB-NFIB knockdown and IGF1R inhibition demonstrated that the majority were also overexpressed in ACC surgical samples (P < .001) ( Figure 5K ). These genes are involved in cell cycle regulation, DNA replication/repair, and cell division ( Figure 5L ).
Discussion
The MYB-NFIB gene fusion, which encodes a transcriptional master regulator, is the main genomic hallmark of ACC and a potential therapeutic target (5, 10, (16) (17) (18) . Here, we show that pharmacological inhibition of IGF1R leads to an AKT-dependent downregulation of MYB-NFIB expression and markedly decreases the proliferation of ACC cells and their ability to form spheres. To our knowledge, these results are the first to demonstrate that a druggable cell surface receptor regulates a fusion oncogene encoding a transcriptional regulator.
Dysregulation of oncogenic transcription factors plays a key role in the pathogenesis of cancer (31, 32) . However, transcription factors are notoriously difficult to target and there are few feasible approaches to target these regulators, including, for example, siRNA-mediated silencing of gene expression and blocking of protein-protein interactions in transcription complexes (31, 32) . The key observation in our study that IGF1R/AKT inhibition downregulates the transcriptional master regulator MYB-NFIB represents a novel strategy to target transcriptional regulators. siRNA knockdown of MYB-NFIB reduced ACC cell proliferation and spherogenesis and downregulated genes critical for tumor growth, demonstrating that MYB-NFIB is an oncogenic driver that may also regulate the expansion of ACC NFIB knockdown (mean 6 SD, n ¼ 3, independent sample t test, **P < .01, ***P < .001). K) Venn diagram showing statistically significant overlap (chi-square test) between genes downregulated after MYB-NFIB knockdown/IGF1R inhibition and genes overexpressed in ACC surgical samples. L) Gene ontology analysis of the 227 shared genes in (K). All statistical tests were two-sided. ACC ¼ adenoid cystic carcinoma; ES ¼ enrichment score; NES ¼ normalized enrichment score.
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stem/stem-like cancer cells. Like siRNA knockdown of MYB-NFIB, pharmacologic inhibition of IGF1R downregulated target genes and reduced cell proliferation and spherogenesis, supporting the concept that IGF1R is a valid therapeutic target in ACC. Notably, our data indicate that aberrant IGF1R/AKT signaling in ACC is driven by tumor-secreted IGF2. IGF1R is overexpressed also in other cancers and is necessary for transformation induced by several oncogenes, and there is substantial evidence that IGF signaling promotes neoplastic growth (33) . Interestingly, IGF1R signaling is activated by several oncogenic gene fusions, including ETV6-NTRK3, EWSR1-WT1, and CD74-NRG1 (34) (35) (36) . In contrast, our results unexpectedly show that in ACC, IGF1R regulates MYB-NFIB. This finding raises the possibility that also other oncogenic gene fusions may be regulated by druggable RTKs.
Analysis of global gene expression showed that MYB-NFIB knockdown affected more than 1000 genes in ACC cells. Many of these genes were downstream targets of MYC. Our data indicate that MYB-NFIB alters their expression indirectly by regulating MYC protein levels. Thus, the transcriptional program induced by MYB-NFIB also affects critical oncogenic mediators normally controlled by MYC. Therefore, therapies aimed at MYC might also be candidate therapies for ACC. These findings, and the fact that both MYB and MYC bind to large and diverse sets of target genes (6, 37) , indicate that the transcription factors themselves, rather than their downstream effectors, should be targeted.
Like IGF1R activation, we found that EGFR and MET signaling promote growth of ACC cells. Little is known about these signaling pathways in ACC. Mutations in the FGF/IGF/PI3K pathway(s) were reported in a subset of ACCs, but no genomic alterations affecting IGF1R, EGFR, or MET were found (17) . However, immunohistochemical studies have demonstrated expression of EGFR and MET (38, 39) . In our study, linsitinib only slightly reduced the growth of xenografted human ACCs, consistent with the minor response to IGF1R inhibition in an ACC patient (40) . Moreover, EGFR inhibitors have elicited a poor response in ACC patients (19, 20) . However, we found that ACC cells are sensitive to MET inhibition and that cotargeting of EGFR and MET has a synergistic negative effect on the proliferation of ACC cells, indicating crosstalk between these receptors. As we hypothesized, combined targeting of IGF1R, EGFR, and MET statistically significantly reduced MYB expression and the growth of xenografted human ACCs. In addition to being smaller, the TKI-treated tumors showed clear signs of differentiation. Similarly, TKI treatment of cultured ACC cells downregulated MYB and induced differentiation. These results are in agreement with studies showing that MYB knockdown in T-ALL cells with MYB activation induces differentiation (41) . Our findings thus demonstrate the complex nature of receptor signaling in ACC and suggest that multiple pathways, including IGF1R/AKT, must to be targeted to achieve clinical response.
Preclinical investigations of ACC are hampered by the lack of established ACC cell lines and transgenic mouse models. ACC cells are also exceedingly difficult to culture in vitro, thus limiting the number of tumors available for experimental studies. Another limitation is that our TKI treatment of xenografted ACCs resulted in growth inhibition and not apoptosis. This should, however, be considered in light of the fact that there currently is no effective treatment available for patients with recurrent and/or metastatic ACC. Although multitargeted therapies will undoubtedly be required for treatment of many cancers, including ACC, they may cause excess toxicity. Hence, our three-drug combination should be further explored using dose escalation in a phase I clinical trial. An alternative approach is to use drugs targeting multiple kinases such as BMS-754807 that targets both IGF1R and MET.
In summary, we show that the transcriptional master regulator MYB-NFIB is an oncogenic driver that controls proliferation and spherogenesis of ACC cells. Importantly, MYB-NFIB is regulated by AKT-dependent IGF1R signaling, indicating that this pathway is a key target for therapy in ACC. Our studies uncover a new strategy to target an oncogenic transcriptional master regulator that may have therapeutic implications also for other translocation-driven malignancies.
